Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
US12371427B2 · kind B2 · utility
0Cited by
10References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 30, 2020 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Nov 8, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (I), compositions thereof, and methods of using thereof that are described herein are particularly useful for treatment, prevention, and management of several sleep disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.